Brief: Hansa Biopharma Announces Positive Results Of Phase 2 Trial Of Drug Imlifidase
07/12/2023 06:19
Dec 7 (Reuters) - Hansa Biopharma AB HNSA.ST :
* IMLIFIDASE DEMONSTRATED POSITIVE SAFETY, TOLERABILITY, AND
EARLY
EFFICACY OUTCOMES IN 15-HMEDIDES-09 PHASE 2 TRIAL IN
GUILLAIN-BARRÉ SYNDROME (GBS)
* FURTHER ANALYSIS OF EFFICACY DATA WILL BE CONDUCTED IN
2024
Source text for Eikon: ID:nWkr5t1Ygs
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS